EUVIMEDEUVIMED entdecken
Multizentrische Studie

Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

Naokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, Satoshi Yoshioka, Kazunori Imada, Kentaro Fukushima, Masaaki Hotta, Shin-Ichi Fuchida, Junya Kanda, Nobuhiko Uoshima, Yuji Shimura, Hirokazu Tanaka und 16 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05705-z ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Naokazu Nakamura und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Shinko Hospital, 1-4-47, Wakihamacho, Chuo-Ku, Kobe, Hyogo, 651-0072, Japan. n_nakamura@kuhp.kyoto-u.ac.jp. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Elotuzumab-based regimens are sometimes selected for multiple myeloma treatment after daratumumab-based regimens. However, there has been insufficient discussion on the efficacy of elotuzumab after daratumumab. We used Kansai Myeloma Forum registration data in a multicenter retrospective evaluation of the efficacy of elotuzumab after daratumumab. Overall survival (OS) rate and time to next treatment (TTNT) were significantly worse in the cohort given elotuzumab after daratumumab (Dara cohort, n = 47) than in the cohort with no history of daratumumab administration before elotuzumab (No-Dara cohort, n = 80, OS: P = 0.03; TTNT: P = 0.02; best response: P < 0.01). In the Dara cohort, OS and TTNT rates were worse with sequential elotuzumab use after daratumumab than with non-sequential (OS: P = 0.02; TTNT: P = 0.03). In patients given elotuzumab < 180 days after daratumumab, OS (P = 0.08) and best response (P = 0.21) tended to be worse, and TTNT was significantly worse (P = 0.01), than in those given elotuzumab after ≥ 180 days. These findings were confirmed by subgroup analyses and multivariate analyses. Monoclonal-antibody-free treatment might be preferable after daratumumab-based regimens. If possible, elotuzumab-based regimens should be considered only ≥ 180 days after daratumumab use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalHumansRetrospective StudiesFemaleMaleAgedMiddle AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsSurvival RateTreatment OutcomeAdult

Stichwörter der Autor:innen

DaratumumabElotuzumabImmune microenvironmentMultiple myeloma

Substanzen

daratumumabelotuzumabAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Hematology, Shinko Hospital, 1-4-47, Wakihamacho, Chuo-Ku, Kobe, Hyogo, 651-0072, Japan. n_nakamura@kuhp.kyoto-u.ac.jp.
  • Department of Hematology and Oncology Graduate School of Medicine, Kyoto University, Kyoto, Japan. n_nakamura@kuhp.kyoto-u.ac.jp.
  • Department of Hematology, Shinko Hospital, 1-4-47, Wakihamacho, Chuo-Ku, Kobe, Hyogo, 651-0072, Japan.
  • Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
  • Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.

Zitieren

APA

Nakamura, N., Arima, N., Takakuwa, T., Yoshioka, S., Imada, K., Fukushima, K., Hotta, M., Fuchida, S. I., Kanda, J., Uoshima, N., Shimura, Y., Tanaka, H., Ohta, K., Kosugi, S., Yagi, H., Yoshihara, S., Yamamura, R., Adachi, Y., Hanamoto, H., …, & Kansai Myeloma Forum (2024). Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05705-z

Vancouver

Nakamura N, Arima N, Takakuwa T, Yoshioka S, Imada K, Fukushima K, et al. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05705-z

BibTeX
@article{Nakamura2024,
  author = {Nakamura, Naokazu and Arima, Nobuyoshi and Takakuwa, Teruhito and Yoshioka, Satoshi and Imada, Kazunori and Fukushima, Kentaro and Hotta, Masaaki and Fuchida, Shin-Ichi and Kanda, Junya and Uoshima, Nobuhiko and Shimura, Yuji and Tanaka, Hirokazu and Ohta, Kensuke and Kosugi, Satoru and Yagi, Hideo and Yoshihara, Satoshi and Yamamura, Ryosuke and Adachi, Yoko and Hanamoto, Hitoshi and Shibayama, Hirohiko and Hosen, Naoki and Ito, Tomoki and Shimazaki, Chihiro and Takaori-Kondo, Akifumi and Kuroda, Junya and Matsumura, Itaru and Hino, Masayuki and Kansai Myeloma Forum, Kansai Myeloma Forum},
  title = {Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05705-z}
}
Kostenlos starten →